Marksans Pharma Reports Q1 FY26 Revenue of 620 Cr, Up 5% YoY; Strong Cash Position of 711 Cr

Marksans Pharma Ltd. has reported its financial results for the quarter ended on June 30, 2025. The company's revenue stood at Rs. 620 cr., up by 5% YoY, driven mainly by growth in the US market from new product launches in the gastrointestinal, pain management, and digestive health segments. The gross profit stood at Rs. 358.2 cr., up by 8.9% YoY. The company's US & North America Formulation business reported revenues of Rs. 327.6 cr. in Q1FY26. Revenues from the UK & Europe Formulation business in Q1FY26 stood at Rs. 203.8 cr. The Australia and New Zealand business reported revenues of Rs. 57.0 cr. in Q1FY26. The RoW business reported revenues of Rs. 31.6 cr. in Q1FY26. The net cash from operations was at Rs 48.7 cr. in Q1FY26. The cash balance as of 30 June 2025 stood at Rs. 711 cr. The company's research & development (R&D) for Q1FY26 was Rs. 12.1 cr., 2.0% of consolidated revenue.